Literature DB >> 30105469

Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients.

Viktor Rotbain Curovic1, Tine W Hansen2, Mie K Eickhoff2, Bernt Johan von Scholten2, Henrik Reinhard2, Peter Karl Jacobsen3, Frederik Persson2, Hans-Henrik Parving4, Peter Rossing2,5.   

Abstract

AIMS: Urinary levels of kidney injury molecule 1 (u-KIM-1) and neutrophil gelatinase-associated lipocalin (u-NGAL) reflect proximal tubular pathophysiology and have been proposed as risk markers for development of complications in patients with type 2 diabetes (T2D). We clarify the predictive value of u-KIM-1 and u-NGAL for decline in eGFR, cardiovascular events (CVE) and all-cause mortality in patients with T2D and persistent microalbuminuria without clinical cardiovascular disease.
METHODS: This is a prospective study that included 200 patients. u-KIM-1 and u-NGAL were measured at baseline and were available in 192 patients. Endpoints comprised: decline in eGFR > 30%, a composite of fatal and nonfatal CVE consisting of: cardiovascular mortality, myocardial infarction, stroke, ischemic heart disease and heart failure based on national hospital discharge registries, and all-cause mortality. Adjusted Cox models included traditional risk factors, including eGFR. Hazard ratios (HR) are provided per 1 standard deviation (SD) increment of log2-transformed values. Relative integrated discrimination improvement (rIDI) was calculated.
RESULTS: During the 6.1 years' follow-up, higher u-KIM-1 was a predictor of eGFR decline (n = 29), CVE (n = 34) and all-cause mortality (n = 29) in adjusted models: HR (95% CI) 1.68 (1.04-2.71), p = 0.034; 2.26 (1.24-4.15), p = 0.008; and 1.52 (1.00-2.31), p = 0.049. u-KIM-1 contributed significantly to risk prediction for all-cause mortality evaluated by rIDI (63.1%, p = 0.001). u-NGAL was not a predictor of any of the outcomes after adjustment.
CONCLUSIONS: In patients with T2D and persistent microalbuminuria, u-KIM-1, but not u-NGAL, was an independent risk factor for decline in eGFR, CVE and all-cause mortality, and contributed significant discrimination for all-cause mortality, beyond traditional risk factors.

Entities:  

Keywords:  Albuminuria; Biomarkers; Cardiovascular; Diabetic kidney disease; Diabetic nephropathy; Type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 30105469     DOI: 10.1007/s00592-018-1205-0

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  9 in total

1.  Novel Urinary Glycan Biomarkers Predict Cardiovascular Events in Patients With Type 2 Diabetes: A Multicenter Prospective Study With 5-Year Follow Up (U-CARE Study 2).

Authors:  Koki Mise; Mariko Imamura; Satoshi Yamaguchi; Mayu Watanabe; Chigusa Higuchi; Akihiro Katayama; Satoshi Miyamoto; Haruhito A Uchida; Atsuko Nakatsuka; Jun Eguchi; Kazuyuki Hida; Tatsuaki Nakato; Atsuhito Tone; Sanae Teshigawara; Takashi Matsuoka; Shinji Kamei; Kazutoshi Murakami; Ikki Shimizu; Katsuhiro Miyashita; Shinichiro Ando; Tomokazu Nunoue; Michihiro Yoshida; Masao Yamada; Kenichi Shikata; Jun Wada
Journal:  Front Cardiovasc Med       Date:  2021-05-24

2.  High Serum Uric Acid Is Associated with Tubular Damage and Kidney Inflammation in Patients with Type 2 Diabetes.

Authors:  Naiara S Guarda; Yãnaí S Bollick; José Antonio M de Carvalho; Melissa O Premaor; Fabio V Comim; Rafael N Moresco
Journal:  Dis Markers       Date:  2019-04-11       Impact factor: 3.434

3.  Renal injury after uninephrectomy in male and female intrauterine growth-restricted aged rats.

Authors:  Ashley D Newsome; Gwendolyn K Davis; Osasu N Adah; Norma B Ojeda; Barbara T Alexander
Journal:  PLoS One       Date:  2019-03-07       Impact factor: 3.240

4.  Editorial: Novel Biomarkers for Type 2 Diabetes.

Authors:  Tarunveer S Ahluwalia; Tuomas O Kilpeläinen; Sandeep Singh; Peter Rossing
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-27       Impact factor: 5.555

Review 5.  Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function".

Authors:  Giuseppe Pugliese; Giuseppe Penno; Andrea Natali; Federica Barutta; Salvatore Di Paolo; Gianpaolo Reboldi; Loreto Gesualdo; Luca De Nicola
Journal:  J Nephrol       Date:  2020-02       Impact factor: 3.902

Review 6.  Diabetic kidney diseases revisited: A new perspective for a new era.

Authors:  Haiyan Fu; Silvia Liu; Sheldon I Bastacky; Xiaojie Wang; Xiao-Jun Tian; Dong Zhou
Journal:  Mol Metab       Date:  2019-10-17       Impact factor: 7.422

7.  The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality.

Authors:  David Ray Chang; Hung-Chieh Yeh; I-Wen Ting; Chen-Yuan Lin; Han-Chun Huang; Hsiu-Yin Chiang; Shih-Ni Chang; Hsiu-Chen Tsai; Yen-Chun Lo; Chiung-Tzu Hsiao; Pei-Lun Chu; Chin-Chi Kuo
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

Review 8.  Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease.

Authors:  Christodoula Kourtidou; Maria Stangou; Smaragdi Marinaki; Konstantinos Tziomalos
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

Review 9.  Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?

Authors:  Xiaodie Mu; Min Yang; Peiyao Ling; Aihua Wu; Hua Zhou; Jingting Jiang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-01-29       Impact factor: 3.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.